{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:01:05Z","timestamp":1793131265733,"version":"4.5.0"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>TRK-950 is a first-in-class humanized antibody targeting cytoplasmic activation\/proliferation-associated protein-1, which is strongly expressed on the cell membrane surface in or on most solid tumors but not in or on normal tissues. This first-in-human study investigated the safety profile, pharmacokinetics (PK), and preliminary antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients with treatment-refractory, locally advanced, or metastatic solid tumors were enrolled in a dose escalation\/expansion study. TRK-950 was administered intravenously weekly for 3 weeks in a 28-day cycle, with doses ranging from 3 to 30 mg\/kg. Dose expansion included 10 mg\/kg weekly and 30 mg\/kg biweekly for colorectal cancer and 10 mg\/kg weekly for cholangiocarcinoma. The primary objective of this study was to determine its safety, tolerability, and maximum tolerated dose. The secondary objectives were PK, preliminary antitumor activity, and identification of potential biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-six patients received at least one dose of TRK-950. In the dose escalation cohort, the maximum tolerated dose was not reached, and no dose-limiting toxicities were observed up to 30 mg\/kg. Common adverse events included abdominal pain, fatigue, constipation, back pain, nausea, and decreased appetite. TRK-950 exhibited a PK profile similar to that of other IgG subclass 1 therapeutic antibodies, with linear PK parameters over the 3 to 30 mg\/kg dose range. The best response was stable disease. Notably, one patient with cholangiocarcinoma showed signs of cavitation after approximately 8 months, suggesting potential antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TRK-950 is safe and well tolerated, has a favorable PK profile, and should be further investigated as a monotherapy and in combination with standard treatment for various types of solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>TRK-950, a humanized antibody targeting CAPRIN-1, demonstrated good tolerability, no dose-limiting toxicities, a favorable PK profile, and potential antitumor activity in this first-in-human study. Currently, TRK-950 is undergoing Phase Ib and II trials for various cancers, showing promising development potential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0123","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T07:51:53Z","timestamp":1750837913000},"page":"1119-1128","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-1688","authenticated-orcid":false,"given":"Philippe A.","family":"Cassier","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Centre L\u00e9on B\u00e9rard & Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-2658","authenticated-orcid":false,"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[{"name":"2Department of Hematology-Oncology, Mayo Clinic Arizona, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-5985","authenticated-orcid":false,"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[{"name":"3HonorHealth Research Institute, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7859-4975","authenticated-orcid":false,"given":"Bertrand","family":"Dubois","sequence":"additional","affiliation":[{"name":"4Lyon Immunotherapy for Cancer Laboratory, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL) INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-833X","authenticated-orcid":false,"given":"Christophe","family":"Caux","sequence":"additional","affiliation":[{"name":"4Lyon Immunotherapy for Cancer Laboratory, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL) INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-4734","authenticated-orcid":false,"given":"Fumiyoshi","family":"Okano","sequence":"additional","affiliation":[{"name":"5Toray Industries, Inc., New Frontiers Research Laboratories, Kamakura, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4723-7681","authenticated-orcid":false,"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[{"name":"6Translational Genomics Research Institute (TGen) A Part of City of Hope, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"7Department of Medical Oncology, Centre L\u00e9on B\u00e9rard & Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL) & Universit\u00e9 Claude Bernard Lyon 1, Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"2025071100302282200_bib1","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.4049\/jimmunol.172.4.2389","article-title":"Activation\/division of lymphocytes results in increased levels of cytoplasmic activation\/proliferation-associated protein-1: prototype of a new family of proteins","volume":"172","author":"Grill","year":"2004","journal-title":"J Immunol"},{"key":"2025071100302282200_bib2","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.4049\/jimmunol.175.7.4274","article-title":"Absence of caprin-1 results in defects in cellular proliferation","volume":"175","author":"Wang","year":"2005","journal-title":"J Immunol"},{"key":"2025071100302282200_bib3","doi-asserted-by":"crossref","first-page":"e1004242","DOI":"10.1371\/journal.ppat.1004242","article-title":"G3BP1, G3BP2 and CAPRIN1 are required for translation of interferon stimulated mRNAs and are targeted by a dengue virus non-coding RNA","volume":"10","author":"Bidet","year":"2014","journal-title":"PLoS Pathog"},{"key":"2025071100302282200_bib4","doi-asserted-by":"crossref","first-page":"e39338","DOI":"10.1371\/journal.pone.0039338","article-title":"Fragile X mental retardation protein interacts with the RNA-binding protein Caprin1 in neuronal RiboNucleoProtein complexes [corrected]","volume":"7","author":"El Fatimy","year":"2012","journal-title":"PLoS One"},{"key":"2025071100302282200_bib5","doi-asserted-by":"crossref","first-page":"e00474","DOI":"10.1128\/JVI.00474-17","article-title":"Zika virus hijacks stress granule proteins and modulates the host stress response","volume":"91","author":"Hou","year":"2017","journal-title":"J Virol"},{"key":"2025071100302282200_bib6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.yexcr.2008.11.011","article-title":"Microtubule-dependent association of AKAP350A and CCAR1 with RNA stress granules","volume":"315","author":"Kolobova","year":"2009","journal-title":"Exp Cell Res"},{"key":"2025071100302282200_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jnc.13768","article-title":"Preferential binding of a stable G3BP ribonucleoprotein complex to intron-retaining transcripts in mouse brain and modulation of their expression in the cerebellum","volume":"139","author":"Martin","year":"2016","journal-title":"J Neurochem"},{"key":"2025071100302282200_bib8","doi-asserted-by":"crossref","first-page":"e29677","DOI":"10.7554\/eLife.29677","article-title":"RNG105\/caprin1, an RNA granule protein for dendritic mRNA localization, is essential for long-term memory formation","volume":"6","author":"Nakayama","year":"2017","journal-title":"Elife"},{"key":"2025071100302282200_bib9","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1523\/JNEUROSCI.6386-09.2010","article-title":"RNG105 deficiency impairs the dendritic localization of mRNAs for Na+\/K+ ATPase subunit isoforms and leads to the degeneration of neuronal networks","volume":"30","author":"Shiina","year":"2010","journal-title":"J Neurosci"},{"key":"2025071100302282200_bib10","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/MCB.02300-06","article-title":"Distinct structural features of caprin-1 mediate its interaction with G3BP-1 and its induction of phosphorylation of eukaryotic translation initiation factor 2alpha, entry to cytoplasmic stress granules, and selective interaction with a subset of mRNAs","volume":"27","author":"Solomon","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2025071100302282200_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1107\/S2059798316004903","article-title":"Crystal structure of a dimerization domain of human Caprin-1: insights into the assembly of an evolutionarily conserved ribonucleoprotein complex consisting of Caprin-1, FMRP and G3BP1","volume":"72","author":"Wu","year":"2016","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"2025071100302282200_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.biopha.2013.06.006","article-title":"Caprin-1 is a novel microRNA-223 target for regulating the proliferation and invasion of human breast cancer cells","volume":"67","author":"Gong","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"2025071100302282200_bib13","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3892\/ol.2020.11712","article-title":"Caprin-1 promotes HepG2 cell proliferation, invasion and migration and is associated with poor prognosis in patients with liver cancer","volume":"20","author":"Guo","year":"2020","journal-title":"Oncol Lett"},{"key":"2025071100302282200_bib14","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.18632\/oncotarget.3236","article-title":"Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget","volume":"6","author":"Qiu","year":"2015","journal-title":"Oncotarget"},{"key":"2025071100302282200_bib15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.bbadis.2013.03.014","article-title":"Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice","volume":"1832","author":"Sabile","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"2025071100302282200_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12943-019-1096-x","article-title":"Prostate cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly","volume":"18","author":"Shi","year":"2019","journal-title":"Mol Cancer"},{"key":"2025071100302282200_bib17","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.prp.2017.07.014","article-title":"Upregulation of caprin1 expression is associated with poor prognosis in hepatocellular carcinoma","volume":"213","author":"Tan","year":"2017","journal-title":"Pathol Res Pract"},{"key":"2025071100302282200_bib18","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1038\/ncomms14448","article-title":"MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression","volume":"8","author":"Teng","year":"2017","journal-title":"Nat Commun"},{"key":"2025071100302282200_bib19","first-page":"15","article-title":"Role of caprin-1 in carcinogenesis","volume":"18","author":"Yang","year":"2019","journal-title":"Oncol Lett"},{"key":"2025071100302282200_bib20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1158\/2767-9764.CRC-22-0310","article-title":"Identification of membrane-expressed CAPRIN-1 as a novel and universal cancer target, and generation of a therapeutic anti-CAPRIN-1 antibody TRK-950","volume":"3","author":"Okano","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2025071100302282200_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2025071100302282200_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"key":"2025071100302282200_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025071100302282200_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"2025071100302282200_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2025071100302282200_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10928-009-9120-1","article-title":"Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis","volume":"36","author":"Krippendorff","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2025071100302282200_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ"},{"key":"2025071100302282200_bib28","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0123\/3626144\/crc-25-0123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/7\/1119\/3630090\/crc-25-0123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/7\/1119\/3630090\/crc-25-0123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:30:29Z","timestamp":1752208229000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/7\/1119\/763525\/Phase-I-First-in-Human-Study-of-TRK-950-an-IgG1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0123","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29539922","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539910","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539931","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539898","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539904","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539937","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539925","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539913","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539934","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539901","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539919","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539907","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539928","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29539916","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7922531","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}